Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M872Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-5.4EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)16.9Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %3.6PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54,250,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PID

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

PID is held by these investors:

PID: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.4869.62view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94-5.08view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.179358.82view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.361082.35view
Bebek, IvanDirector 2017-01-16Buy8,990$3.38375.74view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.413821.95view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91-42.39view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27156.46view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-73.37view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1510620view

Quarterly/Annual Reports about PID:

    News about PID:

    Articles On GuruFocus.com
    Searching The World For The Best Dividend Stocks Jan 06 2015 

    More From Other Websites
    The Zacks Analyst Blog Highlights: SDIV, DWX, LVL, FGD and PID Sep 14 2017
    How TEVA’s CNS Drugs Performed in 1H17 Sep 14 2017
    5 Hot Global Dividend ETFs Sep 13 2017
    How TEVA’s Generic Medicines Franchise Is Positioned after 1H17 Sep 13 2017
    How ONEOK Has Managed Its Impressive Dividend Yield Sep 11 2017
    What Happened to Novartis’s Innovative Medicines Business in 2Q17? Aug 30 2017
    Global Dividend Payments Upbeat in Q2: ETFs to Benefit Aug 30 2017
    Dividend Yield of Stanley Black & Decker Aug 23 2017
    A Look at Sanofi Pasteur’s Performance in 2Q17 Aug 18 2017
    North America: Fresenius Medical Care’s Major Target Market in 2017 Aug 18 2017
    Sanofi Genzyme Continues Driving Revenue Growth in 2Q17 Aug 17 2017
    Kimberly-Clark’s Dividend Growth Aug 16 2017
    Novartis in 2Q17: Performance of Sandoz Jul 25 2017
    Analysts Expect Novartis’s Revenues to Fall in 2Q17 Jul 17 2017
    What Makes This Global Dividend Income ETF So Popular Jun 13 2017
    Inside Novartis’s Segment-Wise Performance in 1Q17 Jun 01 2017
    Performance of Sanofi’s Established Prescription Products in 1Q17 May 29 2017
    Don't Sell, Buy 4 High Dividend ETFs Under $20 in May May 02 2017
    How GlaxoSmithKline’s Vaccines Business Performed in 1Q17 May 02 2017
    How GlaxoSmithKline’s Business Segments Performed in 1Q17 May 01 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat